EFB Dengue Literature Review

CXCR5

9 min read

CXCR5

Overview

CXCR5 is a chemokine receptor for CXCL13, the follicle-associated chemokine. CXCR5 expression enables B cells to home to B cell follicles in secondary lymphoid organs. Its presence or absence on IgD⁻CD27⁻ (DN) B cells is the primary criterion for discriminating DN1 (CXCR5⁺, follicle-homing) from DN2 (CXCR5⁻, extrafollicular) subsets.

Key Points from Literature

  • DN1/DN2 discrimination: CXCR5 vs. CD19 on pre-gated IgD⁻CD27⁻ cells separates DN1 (CXCR5⁺, CD19 intermediate) from DN2 (CXCR5⁻, CD19^hi). In healthy donors, DN1 (CXCR5⁺) is the majority; in active SLE, DN2 (CXCR5⁻) dominates (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • CXCR5 absence as extrafollicular marker: Loss of CXCR5 on DN2 cells is consistent with exclusion from B cell follicles — a hallmark of extrafollicular effector B cells. aNAV cells also lack CXCR5 (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • Transcriptional validation: CXCR5 is among the genes uniquely low in DN2 cells by RNA-seq, with ZEB1 binding motifs enriched in genes with low DN2 expression including CXCR5 (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • NAV and SWM subsets also stratified by CXCR5: Within NAV cells, rNAV are CXCR5⁺ while aNAV are CXCR5⁻. Within SWM, the majority are CXCR5⁺. CXCR5 loss thus marks the extrafollicular activation state across multiple B cell subsets (see Jenks2018 - DN2 B Cells and EF Pathway in SLE).

  • CXCR5 can substitute for CD21 in gating: CXCR5 vs. CD11c staining identifies the same B cell subsets as CD21 vs. CD11c (DN1/DN2 in DN gate; resting vs. activated in naive and memory gates). This substitutability provides practical flexibility for panel design when CD21 reagents are unavailable (see Sanz2025 - Human Atypical B Cells Overview, review, Figure 2B–C).

  • CXCR5 decreased in EF populations during acute COVID-19: In CoV-A patients, CXCR5 surface expression was reduced on EF populations (aN, DN2) relative to follicular populations (rN, DN1). Concurrently, CXCR3 (IFN-γ-driven tissue homing receptor) was increased on the same populations. This reciprocal CXCR5↓/CXCR3↑ switch is the most direct in vivo evidence in human infection that EF pathway B cells are programmed for inflammatory tissue homing rather than follicular entry (see Woodruff2020 - EF B Cell Responses in COVID-19, spectral FCM, n=9 CoV-A patients).

  • CXCR5 included in 24-marker spectral B cell panel: CXCR5 was part of the homing marker module (alongside CXCR3, CXCR4, CD62L) in the standardised Woodruff2020 panel design (see Woodruff2020 - EF B Cell Responses in COVID-19, Table 1 / Supplementary Table 1).

  • CXCR5⁺ pre-GC TFH cells present but Bcl-6⁺CXCR5⁺ GC-TFH near-absent in COVID-19: In post-mortem COVID-19 lymphoid tissue, CD4⁺CXCR5⁺ pre-GC TFH cells were present but reduced, while CD4⁺Bcl-6⁺CXCR5⁺ GC-type TFH cells were strikingly depleted (LN: p<0.001; spleen: p<0.01). This indicates a specific block in the final maturation step from pre-GC (Bcl-6⁻CXCR5⁺) to GC-TFH (Bcl-6⁺CXCR5⁺), occurring at the T-B interface where excessive TNF-α may prevent Bcl-6 upregulation (see Kaneko2020 - GC Loss and TFH Block in COVID-19, n=11 COVID + controls, multi-color immunofluorescence).

  • CXCR5 absence defines Tph cells in dengue: The dominant activated CD4⁺ T cell subset in acute dengue is CXCR5⁻PD-1⁺ (Peripheral Helper T Cell), not CXCR5⁺PD-1⁺ (cTfh). ~75% of activated CD4⁺ T cells lack CXCR5. CXCR5 absence on both Tph (T cells) and DN2 (B cells) positions CXCR5 loss as the unifying marker of EF pathway commitment across both lymphocyte lineages (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue, n=170 acute dengue).

  • Concurrent CXCL13 elevation despite Tph dominance: Despite the overwhelming dominance of CXCR5⁻ Tph cells, plasma CXCL13 (the CXCR5 ligand and GC biomarker) is elevated in acute dengue. This suggests concurrent GC activity alongside the dominant EF response — EF and GC may not be mutually exclusive in dengue (see Ansari2025 - Peripheral T Helper Subset Drives B Cell Response in Dengue).

  • CXCR5 is the top axis of the four-subset DN classification. In the DN1–DN4 scheme, CXCR5 splits the compartment into follicle-competent (CXCR5⁺: DN1, DN4) and extrafollicular (CXCR5⁻: DN2, DN3) halves. Only the CXCR5⁻ subsets (DN2, DN3) are tied to EF responses and autoimmunity — so CXCR5⁻-focused gating that targets EF cells will systematically exclude DN1 and DN4 (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Sachinidis & Garyfallos 2021 / Somers 2022 / Castleman 2022; Double-Negative B Cell).

  • CXCR5 dynamics across the phases of a response (mouse-derived framework). Naive follicular B cells are CXCR5^hi and require it to home to CXCL13 in the follicle. Within ~6 h of cognate antigen engagement, activated B cells decrease CXCR5 while increasing EBI2 and CCR7, moving to the T-B border. Cells committing to a GC fate then re-establish CXCR5-dominant positioning (with CXCR4) to move to the follicle centre, adding S1PR2 and P2RY8 for confinement. Cells following a GC-independent path instead further decrease CXCR5 and elevate CXCR4 without S1PR2 as they differentiate into plasmablasts. CXCR5 is therefore low at two quite different moments — early activation and plasmablast differentiation — and high in between for GC cells (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data).

  • ★ [2026-08-27] CXCR5 is one of only two axes that define the DN1–DN4 quadrant scheme. In the Pillai/Ragon classification, IgD⁻CD27⁻ cells are split by CXCR5 × CD11c alone: DN1 = CXCR5⁺CD11c⁻, DN2 = CXCR5⁻CD11c⁺, DN3 = CXCR5⁻CD11c⁻, DN4 = CXCR5⁺CD11c⁺ (Fig. 1B/1C quadrants; confirmed by the tissue marker-validation panel Fig. 6C). No CD21 and no T-bet are in that panel — so in this lineage of the literature, CXCR5 carries the entire follicular-competence axis by itself. This differs from the Emory/Sanz DN3 gate (CD11c⁻CD21⁻), and the two axes have never been run on the same sample (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=38, 13-colour FCM). See DN3 B Cell Contradictions.

  • ★ [2026-08-27] STAINING PEARL — CXCR5 clone J252D4 is 3D-conformation-dependent and must be stained at 37 °C. The protocol stained CXCR5 first, at 37 °C, “as the clone J252D4 highly depends on its target protein’s 3D conformation,” with the remainder of the panel stained separately at 4 °C. Brilliant Stain Buffer was included to suppress polymer-dye interaction. This independently corroborates the 37 °C pre-fix instruction already specified for CXCR5 in B Cell Panel Variant 1, and supplies a mechanistic reason for it — conformational epitope loss, not merely receptor internalisation (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, methods).

  • [2026-08-27] CXCR5 also partitions the switched-memory compartment, and that partition moves with disease. Splitting IgD⁻CD27⁺ cells into CXCR5⁺ (classic/resting switched memory) and CXCR5⁻ (“ABC-like”), IgG4-RD blood showed classic SWM decreased and the CXCR5⁻ fraction expanded (both p<0.01, n=38). ⚠ That CXCR5⁻ “ABC-like” gate is CD27-positive and includes both CD11c⁺ and CD11c⁻ cells, so it is not a DN population (see Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues, n=38).

  • This is the wiki’s earliest source for subgating the DN compartment on CXCR5 — the axis the DN1–DN4 scheme was later built on. Figure 2D states plainly that “the DN population can be further defined by markers such as CXCR5”, and Table 1 gives DN1 as CXCR5⁺ and DN2 as CXCR5⁻ (with activated naive also CXCR5⁻). Note what is not claimed: Sanz2019 uses CXCR5 alongside CD38/CD24/CD21, whereas Allard-Chamard2023 - DN3 B Cells Infiltrate Inflamed Tissues later partitions DN on CXCR5 × CD11c with no CD21 at all — the two schemes share this marker but not the partition (see Sanz2019 - Consistent Classification of Human B Cell Populations, review — no original data). See DN2 Gating Strategy.

  • CXCR5 is lost during the IFN-γ-driven conversion — follicular exclusion is an induced state here, not a starting property. Naive B cells entering the cocktail are CXCR5⁺; by day 6 the T-bet^hi^ product is CXCR5^neg^, and the paper uses CXCR5 with CD11c as the axis separating patient DN2 (CD11c^hi^CXCR5^neg^) from DN1 (CD11c^lo^CXCR5⁺) (see Zumaquero2019 - IFN-gamma Programs T-bet-hi B Cells for ASC Differentiation, human, n=20 HD + n=40 SLE + in vitro reconstruction). Because the starting population is uniform naive B cells, this is direct evidence that CXCR5 downregulation is driven by the cytokine environment rather than marking a pre-existing lineage — which bears on the wiki’s CXCR5-vs-CD21 gating-axis conflict.

Contradictions & Debates

  • ★ CXCR5-negativity is not a marker of an extrafollicular response. The wiki has repeatedly used loss of CXCR5 (follicular homing) as the phenotypic signature of extrafollicular commitment — including in the Woodruff2020 CXCR5→CXCR3 chemokine-receptor-shift finding. The consensus Perspective states that absence of CXCR5, together with low SHM, low BCR affinity, and IgM isotype, are each individually non-definitive “as they can be observed in B cells that have participated in a GC response” — and that GC B cells themselves depend on CXCR5 for positioning within the GC, so CXCR5 is not simply a follicular-versus-extrafollicular switch. Compounding this, low CXCR5 may reflect recent activation rather than a permanent state (see Eisenbarth2025 - A Roadmap for Defining Extrafollicular B Cell Responses, consensus Perspective, 12 authors, no primary data). The chemokine-receptor shift remains a real and reproducible observation; what it cannot do alone is locate the response. See GC-Independent Response.

DN2 B Cell, DN3 B Cell, Double-Negative B Cell, Age-Associated B Cell, Activated Naive B Cell, CD11c, CD21, CXCR3, Extrafollicular Response, Germinal Center, Peripheral Helper T Cell, PD-1, GC-Independent Response, Follicular Exclusion

Sources

Graph View

Backlinks